Invitrogen Inks Cancer Dx Pact with Signalomics; Welcomes Competition from Emerging Rivals

Invitrogen has a variety of tools and technologies that it has acquired over the past couple of years that it believes can be employed in the roughly $2 billion molecular diagnostics space. Included among those technologies are assets, which are being used in the collaboration with Signalomics, gained through the acquisition of BioCrystal s BioPixels unit in October 2005. Subscribers: click headline for more

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.